Literature DB >> 16984062

The economics of blood: gift of life or a commodity?

Panos Kanavos1, John Yfantopoulos, Christina Vandoros, Costantina Politis.   

Abstract

OBJECTIVES: To calculate the costs of blood collection, testing, storage, and transfusion in Greece.
METHODS: Costing information was collected from two large public hospitals, in Athens and Crete, that also act as blood banks. Given that private health care accounts for 40 percent of total health spending, the same costs were also considered in a private setting by collecting key reagent cost data from a leading private hospital in Athens. Mainly direct costs were considered (advertising campaigns, personnel, storage and maintenance, reagent costs, transportation costs from blood bank to end-use hospitals, and cross-matching and transfusion costs in receiving hospitals) and some indirect costs (opportunity cost of blood donorship).
RESULTS: Captive donorship accounts for over 50 percent of the national blood supply. A unit of blood transfused would cost between Euro 294.83 and Euro 339.83 in public hospitals and could reach Euro 413.93 in a private facility. This figure may be an underestimate, as it excludes opportunity costs of blood transfusion for patients and the healthcare system.
CONCLUSIONS: Blood has a significant cost to the health system. Policy makers and practitioners should encourage its rational use, build on current policies to further improve collection and distribution, encourage further volunteer donorship in Greece, and also consider alternatives to blood where the possibility exists.

Entities:  

Mesh:

Year:  2006        PMID: 16984062     DOI: 10.1017/s0266462306051233

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  7 in total

1.  Cost of post-operative intravenous iron therapy in total lower limb arthroplasty: a retrospective, matched cohort study.

Authors:  Manuel Muñoz; Susana Gómez-Ramírez; Elisa Martín-Montañez; Enrique Naveira; Javier Seara; José Pavía
Journal:  Blood Transfus       Date:  2013-10-03       Impact factor: 3.443

2.  Blood management by transfusion triggers: when less is more.

Authors:  Sana Ansari; Arpad Szallasi
Journal:  Blood Transfus       Date:  2011-06-15       Impact factor: 3.443

3.  Cost-effectiveness of leucoreduction for prevention of febrile non-haemolytic transfusion reactions.

Authors:  Argirios E Tsantes; Elias Kyriakou; Georgios K Nikolopoulos; Dimitrios Stylos; Marlene Sidhom; Stefanos Bonovas; Panagiota Douramani; Dimitrios Kalantzis; Styliani Kokoris; Serena Valsami; Konstantinos Stamoulis; Marianna Politou; Leontini Foudoulaki-Paparizos
Journal:  Blood Transfus       Date:  2014-04       Impact factor: 3.443

Review 4.  Hemoglobin level at initiation of darbepoetin alfa: impact on need for transfusion and associated costs in chemotherapy-induced anemia treatment in Europe.

Authors:  Melike Deger; Wolfgang Eisterer; Lucie Kutikova; Sam Salek
Journal:  Support Care Cancer       Date:  2012-07-24       Impact factor: 3.603

5.  Economic evaluation of intravenous iron treatments in the management of anemia patients in Greece.

Authors:  Vassilis Fragoulakis; Georgia Kourlaba; Dimitris Goumenos; Manousos Konstantoulakis; Nikolaos Maniadakis
Journal:  Clinicoecon Outcomes Res       Date:  2012-05-04

6.  Making patient blood management the new norm(al) as experienced by implementors in diverse countries.

Authors:  Axel Hofmann; Donat R Spahn; Anke-Peggy Holtorf
Journal:  BMC Health Serv Res       Date:  2021-07-02       Impact factor: 2.655

7.  Budget impact analysis on erythropoiesis-stimulating agents use for the management of chemotherapy-induced anaemia in Greece.

Authors:  Eleftheria Nikolaidi; Magdalini Hatzikou; Mary Geitona
Journal:  Cost Eff Resour Alloc       Date:  2013-07-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.